Author

A. Orlova

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1

Frequent Co-Authors

R. Moriggl· 3 shared B. Wingelhofer· 2 shared H. A. Neubauer· 2 shared A. Bergthaler· 1 shared A. Carracedo· 1 shared A. Ianevski· 1 shared A. Lercher· 1 shared A. Popa· 1 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

R. Moriggl

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Small molecule STAT3/5 inhibitors exhibit therapeutic potential in acute myeloid leukemia and extra-nodal natural killer/T cell lymphoma

D. Pölöske, H. Sorger, A. Schönbichler, E. D. de Araujo, H. A. Neubauer, A. Orlova, S. H. Timonen, D. I. Abdallah, A. Ianevski, H. Kuusanmäki, M. Surbek, C. Wagner, T. Suske, M. L. Metzelder, M. Bergmann, , R. Moriggl

This study evaluates small molecule STAT3/5 inhibitors for treating AML and NKCL, showing growth arrest and synergy with existing therapies in vitro and in vivo.

bioRxiv · Oct 12, 2023 · PreprintCancer Biology

STAT3 restricts prostate cancer metastasis and antiandrogen resistance by controlling LKB1/CREB signaling pathway

J. Pencik, C. Philippe, M. Schlederer, M. Pecoraro, S. Grund-Groeschke, W. J. Li, A. Tracz, I. Heidegger, S. Lagger, K. Trachtova, M. Oberhuber, E. Heitzer, O. Osman, H. A. Neubauer, B. Wingelhofer, , C. McKinney

This study identifies STAT3's role in restricting prostate cancer metastasis and antiandrogen resistance by regulating the LKB1/CREB signaling pathway in mouse models and human patients.

bioRxiv · Aug 25, 2022 · PreprintCancer Biology

The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease

L. Kosack, B. Wingelhofer, A. Popa, B. Vilagos, A. Orlova, P. Majek, K. Parapatics, A. Lercher, B. Agerer, A. Ringler, J. Klughammer, M. Smyth, K. Khamina, H. Baazim, D. A. Rosa, , A. Bergthaler

This study identifies the ERBB-STAT3 axis as a driver of Tasmanian devil facial tumor disease and proposes a dual chemo-immunotherapeutic strategy.

bioRxiv · Apr 12, 2018Cancer Biology